Fig. 2.

Hybrid drug co-targeting strategy and chemical structures are indicated. a Schematic representation of a hybrid drug capable of targeting simultaneously both ER and NFκB and its potential benefit in breast cancer. b Chemical structures of the parent drugs, raloxifene and dimethyl fumarate (DMF), along with the co-targeting drugs are shown. The fumarate moiety of Ral-Fum hybrids is highlighted